- The German biotechnology investment group BB Biotech AG has beenlisted on the Frankfurt stock exchange's "new" market. Market capitalization is around 1 billion Deutschemarks ($562.2 million). Financing is currently divided between BioChem Pharma (31% shares), Transkaryotic Therapies (12%), Genzyme (9%), Aviron (8%) and Amgen and smaller companies (32%).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze